SMNDC1 (Survival Motor Neuron domain-containing protein 1), also known as SMNR or Gemini3. is a component of the survival motor neuron (SMN) complex involved in RNA metabolism and spliceosome assembly. It plays a role in pre-mRNA splicing by facilitating the interaction between small nuclear ribonucleoproteins (snRNPs) and the spliceosome. SMNDC1 antibodies are essential tools for studying its expression, localization, and functional interactions in cellular processes. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to detect SMNDC1 in various biological samples. Research has linked SMNDC1 to spinal muscular atrophy (SMA) due to its association with SMN1/SMN2 genes, where deficiencies cause motor neuron degeneration. Additionally, SMNDC1 is implicated in cancer biology, with studies suggesting roles in tumor progression, DNA repair, and telomere maintenance. Its dysregulation has been observed in malignancies like glioblastoma and hepatocellular carcinoma. SMNDC1 antibodies help elucidate its molecular mechanisms, including interactions with proteins like DEAD-box helicases and components of the SMN complex. These studies contribute to understanding diseases related to RNA processing defects and potential therapeutic targets. Commercial SMNDC1 antibodies are typically developed in hosts like rabbits or mice, with validation across species such as human, mouse, and rat.